Generated by AI
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.
Website225 NE Mizner Blvd.
Boca Raton, FL, 33432
United States
The latest articles about INMB.
Summary of Oct 21's posts. Generated by AI.
Summary of Jun 25's posts. Generated by AI.
Summary of Jun 30's posts. Generated by AI.
Summary of Aug 4's posts. Generated by AI.
Investors talking about INMB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.